← Eichor
Condition: Braf V600 Mutation Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Braf V600 Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
EARLY_Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT04741997Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation
Phase 1 · 13 location(s) · Haisco Pharmaceutical Group Co., Ltd. · NCT06536400Dabrafenib and/or Trametinib Rollover Study
Phase 4 · 32 location(s) · Novartis Pharmaceuticals · NCT03340506Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
Phase 1 · 4 location(s) · Rina Plattner · NCT04903119A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
Phase N/A · 1 location(s) · Fudan University · NCT06749015Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation
Phase 1 · 6 location(s) · Haisco Pharmaceutical Group Co., Ltd. · NCT07158710Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Phase 2 · 1 location(s) · Guangdong Provincial People's Hospital · NCT05800340Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
Phase 2 · 7 location(s) · University of California, San Francisco · NCT07110246Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation
Phase 1 · 2 location(s) · Haisco Pharmaceutical Group Co., Ltd. · NCT07561554
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.